Previous close | 12.28 |
Open | 12.21 |
Bid | 12.89 x 800 |
Ask | 13.98 x 800 |
Day's range | 11.85 - 13.08 |
52-week range | 9.56 - 31.46 |
Volume | |
Avg. volume | 1,057,750 |
Market cap | 917.125M |
Beta (5Y monthly) | 1.58 |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
Shares of Zentalis Pharmaceuticals (NASDAQ: ZNTL) were down 13.5% for the week as of Friday afternoon, according to data provided by S&P Global Market Intelligence. The stock's prices were likely driven down by lowered investor sentiment due to a rash of insider selling. Zentalis is a clinical-stage biotech company that focuses on small-molecule therapies to treat cancer, specifically cancers with broad patient populations.
The consensus price target hints at a 95.7% upside potential for Zentalis Pharmaceuticals, Inc. (ZNTL). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.